Don't forget to factor in a non-NA partnership(s) for Ponatinib. Because it will probably involve significant upfronts, it could have a very positive effect on the share price.
And MRK might have some more data coming out on the other trials of Rida in other cancer indications.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.